GE HealthCare has announced a $138m investment to expand its contrast media manufacturing site in Carrigtohill, Cork, Ireland.
Contrast media are injectable diagnostic imaging agents used to improve the visualisation of blood vessels, organs and tissues during medical imaging.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The 3,000m² facility will feature manufacturing technologies, including a new filling line, multi-functional powder handling systems, autoclaves, and solution preparation vessels, all integrated with ‘advanced’ automation systems to bolster production.
Both existing and pipeline products will be supported by the new facility.
Engineering company IPS-Integrated Project Services will spearhead the construction project, with works commencing this month.
The expansion is expected to create more than 250 construction jobs and boost production capacity by 25 million patient doses annually by the end of 2027.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe global demand for iodine-based contrast media, used in computed tomography (CT), X-ray and interventional procedures, is projected to double in the next ten years. This surge is attributed to ageing populations and a rise in chronic disorders.
GE HealthCare Ireland managing director and site leader Eugene Barrett said: “This expansion strengthens our longstanding presence in Cork, where we have a highly skilled team, access to leading talent in the pharmaceutical industry, strong distribution links around the world and a great partnership with IDA Ireland.
“First doses from our new facility are expected by the end of 2027 and we are proud of the impact our site will continue to make for patients.”
GE HealthCare’s manufacturing processes, from the development of the active pharmaceutical ingredient (API) to the finished product, comply with good manufacturing practices.
Before this development, the company received 510(k) clearance from the US Food and Drug Administration for its enhanced Voluson Expert Series ultrasound systems, which include the Voluson Expert 22, 20, and 18 models.
